| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 19.4 | 19.6 |
| Gross profit | 10.8 | 9.5 |
| Profit before tax | -14.9 | -32.9 |
| Net income | 13.5 | -34.7 |
| EPS (diluted, $ a share) | $0.03 | $-0.09 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -0.9% |
|---|---|
| Gross margin | 55.9% |
| Operating margin | -102.0% |
10-Q filed with the SEC, NASDAQ: LAB. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Standard Biotools Inc.: key numbers
- Share price
- $0.6210Close, Nov 16
- Market cap
- $245M
- Shares outstanding
- 394.79MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Standard Biotools Inc.
All →Standard Biotools M&A Deal with Treeline Biosciences, Inc.
Standard BioTools Inc. provided a status update regarding its pending acquisition of Treeline Biosciences, Inc., specifically addressing stockholder litigation and demand letters. To avoid potential business delays and moot disclosure claims, the company issued supplemental disclosures to its definitive proxy statement ahead of the special meeting of stockholders scheduled for November 19, 2026.
- Counterparty
- Treeline Biosciences, Inc.
Standard Biotools Director Thomas D. Carey Buys $46.9K of Stock
Thomas D. Carey, Director, bought 75,000 shares of Standard Biotools Inc. at $0.6253 a share, worth $46.9K in total on Nov 5, 2026. Shares held after the trade: 419,456 (+21.8%).
- Value
- $46.9K
- Shares
- 75,000
- Price
- $0.6253
- Role
- Director
- Holding change
- +21.8%
- Trade date
- Nov 5, 2026
Standard Biotools Divestiture to Archimed
Standard BioTools Inc. completed the sale of its Microfluidics business to healthcare investment firm ARCHIMED. The divested business will now operate as a standalone independent entity named Biomark Scientific, focusing on high-throughput genomic profiling and microfluidics technology.
- Counterparty
- ARCHIMED
Standard Biotools Divestiture to Archimed
Standard BioTools Inc. has entered into a definitive agreement to sell its Microfluidics business to ARCHIMED, a healthcare-focused investment firm. The transaction is expected to close in approximately 30 days and represents a strategic action to streamline the company's portfolio. Financial terms of the divestiture were not disclosed in the filing.
- Counterparty
- ARCHIMED
Standard Biotools Divestiture to Element Biosystems, LLC for $5.5M
Standard BioTools terminated its previous agreement with Multiplex Bio and entered into a new definitive agreement to sell its mass cytometry business to Element Biosystems for $5.5 million in cash. The board determined the unsolicited offer from GMT Venture was a superior proposal, as it provides higher cash proceeds and eliminates a previously required $10 million working capital loan. The divestiture is expected to close by the end of 2026, concurrently with the company's pending merger with Treeline Biosciences.
- Value
- $5.5M
- Counterparty
- Element Biosystems, LLC (subsidiary of GMT Venture Partners, LLC)